Beth Israel Deaconess Medical Center, Inc.

Beth Israel Deaconess Medical Center, Inc. (doing business as Bidmc) is a Harvard Medical School-affiliated non-profit academic medical center in Boston, Massachusetts that operates as a prime recipient of federal research grants and a subrecipient on complex biomedical research projects, with a portfolio dominated by National Institutes of Health grant funding across cancer, cardiovascular disease, infectious disease, metabolic disease, and aging research domains.

Bidmc competes exclusively full-and-open, without set-aside designations, across a diverse federal grant portfolio. The organization's federal footprint spans 1,875 awards (1,463 prime grants, 412 sub-awards) with 78% in prime capacity, concentrated in research grants rather than contracts. The top customer concentration reflects core NIH funding: the National Institutes of Health and its subsidiary institutes account for 56% of recent award count, led by the NIH Office of the Director ($100 thousand potential value across 479 awards), the National Heart, Lung, and Blood Institute ($357 thousand across 179 awards), and the National Institute of Diabetes and Digestive and Kidney Diseases (150 awards). By potential value, the National Institute of Allergy and Infectious Diseases dominates at $21.8 million across 87 awards, followed by NASA's Shared Services Center at $6.9 million across 19 awards. The two rankings reveal Bidmc's characteristic pattern: many small NIH investigator-initiated grants alongside fewer but larger NIAID awards focused on HIV vaccine and immunology research.

Recent grant activity shows a sustained engagement trajectory: awards per year ranged from 91 in 2022 to 174 in 2024, with 52 awards recorded year-to-date in 2026. Combined potential value across all awards stands at $88.2 million, though actual obligated dollars exceed $3.5 billion—reflecting NIH multi-year award structures where potential values understate total commitment. Within the next 24 months, 151 awards carrying $1.5 million in combined potential value reach completion, creating recompete opportunity primarily in basic biomedical research.

Bidmc's research portfolio is grounded in translational and basic biomedical science spanning multiple disease domains. Representative recent grants illustrate the scope: a $1.68 million NIH Office of the Director award (CFDA 93.310) investigating orexin neuropeptides and menopausal symptom severity in mice (September 2025); an $848 thousand National Heart, Lung, and Blood Institute grant (CFDA 93.837) on cardiac magnetic resonance imaging for coronary microvascular dysfunction (July 2026); a $761 thousand National Institute on Aging award (CFDA 93.866) on epigenetic mechanisms linking delirium and cognitive decline (June 2026); and a $1.99 million Defense Health Agency grant (CFDA 12.420) on barrier antimicrobial defenses in trauma (September 2024). Beyond NIH, Bidmc received a $559 thousand Defense Health Agency award on small molecule therapeutics for colorectal cancer (July 2026) and a $319 thousand National Science Foundation award (CFDA 47.084) establishing an open-source ecosystem for the MindLamp digital phenotyping platform (September 2025). The vendor also holds a single-award Indefinite Delivery Contract with Veterans Integrated Service Network 1 (ceiling $259 thousand, July 2023 through July 2027) for integrated walking and tai chi intervention services for veteran populations, under which three delivery orders have been issued.

Bidmc operates as a prime recipient on the vast majority of its federal awards and subcontracts minimally to other institutions as a named sub on complex projects. In its subcontractor role, Bidmc delivers biomedical research, clinical expertise, and specialized scientific services. Recent sub-awards illustrate this pattern: a subaward to Seattle Children's Hospital on immune mechanisms of protection against Mycobacterium tuberculosis (IMPAC-TB), with Bidmc's Barouch Lab characterizing infection kinetics and vaccine-induced protection in murine models (November 2025); collaboration with Northeastern University on the Patch of Asclepius cybersecure healthcare platform (October 2025); and sub-recipient role under The Johns Hopkins University on HIV reservoir dynamics analysis (June 2026). Across multiple sub-awarded grants to prime recipients (Johns Hopkins, General Hospital Corporation, Harvard Medical School, Stanford University, and others), Bidmc contributes proteomics analysis, clinical site operations, biomarker assessment, data analysis, and manuscript preparation. Service Contract Inventory data, covering federal service contracts above $150,000, shows minimal prime-contract activity (7 SCI records total, 1 as prime, 6 as named sub), with 3.4 FTEs delivered in FY2024—a signal that Bidmc's federal footprint is overwhelmingly grant-funded research rather than service contracts.

Bidmc's corporate structure reflects its position as a child entity within Beth Israel Lahey Health, Inc., a larger non-profit hospital system. The parent company's governance and compliance infrastructure support Bidmc's federal research operations across institutional review boards, regulatory compliance, facilities, and administrative functions. Bidmc's Harvard Medical School affiliation and established reputation in cardiovascular research, infectious disease, aging, and cancer biology drive its sustained competitiveness in NIH peer review and federal grant awards. The organization's research output demonstrates a dual focus on basic mechanistic science (epigenetics, proteomics, genetic engineering in disease models) and translational work bridging laboratory discoveries to clinical applications (biomarker discovery, clinical trials, real-world digital phenotyping platforms). This positioning places Bidmc at the center of the federal biomedical research ecosystem rather than the federal contracting marketplace; the organization pursues grants, not procurement contracts, and builds partnerships as a scientific collaborator rather than a commercial vendor.